scholarly journals Ovarian serous cystadenocarcinoma

2021 ◽  
Author(s):  
Mohammad Niknejad
Keyword(s):  
Serous Cystadenocarcinoma

Hyperamylasemia With Papillary Serous Cystadenocarcinoma Of The Ovary

1989 ◽  
Vol 44 (4) ◽  
pp. 255-258 ◽  
Author(s):  
I. Schlikker ◽  
A. Nakad ◽  
A. Gerbaux ◽  
K. Azzouzi ◽  
J. Kadou ◽  
...  
Keyword(s):  
Serous Cystadenocarcinoma

IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma

2013 ◽  
Vol 13 (6) ◽  
pp. 417-425 ◽  
Author(s):  
Mahyar Malekzadeh ◽  
Alamtaj Samsami Dehaghani ◽  
Abbas Ghaderi ◽  
Mehrnoosh Doroudchi
Keyword(s):  
Serous Cystadenocarcinoma ◽  
Poorly Differentiated

Primary Tubal Serous Cystadenocarcinoma: A Rare Gynaecological Malignancy

2018 ◽  
Vol 7 (5) ◽  
pp. 708-711
Author(s):  
Muniyappa Usha ◽  
◽  
Rau Aarathi R. ◽  
, Mir Tahmida Ali ◽  
◽  
...  
Keyword(s):  
Serous Cystadenocarcinoma ◽  
Gynaecological Malignancy

scholarly journals A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Li-Wei Liu ◽  
Qiuhao Zhang ◽  
Wenna Guo ◽  
Kun Qian ◽  
Qiang Wang
Keyword(s):  
Gene Expression ◽  
Survival Time ◽  
Proportional Hazards ◽  
Gene Expression Signature ◽  
High Specificity ◽  
Cox Proportional Hazards ◽  
Assessment Model ◽  
Serous Cystadenocarcinoma ◽  
Specificity And Sensitivity ◽  
Risk Patients

Ovarian serous cystadenocarcinoma is a common malignant tumor of female genital organs. Treatment is generally less effective as patients are usually diagnosed in the late stage. Therefore, a well-designed prognostic marker provides valuable data for optimizing therapy. In this study, we analyzed 303 samples of ovarian serous cystadenocarcinoma and the corresponding RNA-seq data. We observed the correlation between gene expression and patients’ survival and eventually established a risk assessment model of five factors using Cox proportional hazards regression analysis. We found that the survival time in high-risk patients was significantly shorter than in low-risk patients in both training and testing sets after Kaplan-Meier analysis. The AUROC value was 0.67 when predicting the survival time in testing set, which indicates a relatively high specificity and sensitivity. The results suggest diagnostic and therapeutic applications of our five-gene model for ovarian serous cystadenocarcinoma.

Platinum Chemotherapy during Pregnancy for Serous Cystadenocarcinoma of the Ovary

1993 ◽  
Vol 49 (1) ◽  
pp. 92-94 ◽  
Author(s):  
Cassandra E. Henderson ◽  
Giovanni Elia ◽  
David Garfinkel ◽  
Miriam C. Poirier ◽  
Hanadi Shamkhani ◽  
...  
Keyword(s):  
Serous Cystadenocarcinoma ◽  
Platinum Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document